Literature DB >> 31769104

Managing highly sensitized renal transplant candidates in the era of kidney paired donation and the new kidney allocation system: Is there still a role for desensitization?

Carrie A Schinstock1,2, Byron H Smith3, Robert A Montgomery4, Stanley C Jordan5, Andrew J Bentall1,2, Martin Mai6, Hasan A Khamash7, Mark D Stegall2,8.   

Abstract

Kidney paired donation (KPD) and the new kidney allocation system (KAS) in the United States have led to improved transplantation rates for highly sensitized candidates. We aimed to assess the potential need for other approaches to improve the transplantation rate of highly sensitized candidates such as desensitization. Using the UNOS STAR file, we analyzed transplant rates in a prevalent active waiting-list cohort as of June 1, 2016, followed for 1 year. The overall transplantation rate was 18.9% (11 129/58769). However, only 9.7% (213/2204) of candidates with a calculated panel reactive antibody ≥99.9% received a transplant, and highly sensitized candidates were less likely to receive a living donor transplant. Among candidates with a CPRA ≥ 99.5% (ie. 100%), only 2.5% of transplants were from living donors (13 total, 7 from KPD). Nearly 4 years after KAS (6/30/2018), 1791 actively wait-listed candidates had a CPRA of ≥99.9% and 34.6% (620/1791) of these had ≥5 years of waiting time. Thus, despite KPD and KAS, many sensitized candidates have not been transplanted even with prolonged waiting time. We conclude that candidates with a CPRA ≥ 99.9% and sensitized candidates with an incompatible living donor and prolonged waiting time may benefit from desensitization to improve their ability to receive a transplant.
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  alloantibody; disparities; organ allocation

Mesh:

Substances:

Year:  2019        PMID: 31769104     DOI: 10.1111/ctr.13751

Source DB:  PubMed          Journal:  Clin Transplant        ISSN: 0902-0063            Impact factor:   2.863


  9 in total

Review 1.  Imlifidase for the treatment of anti-HLA antibody-mediated processes in kidney transplantation.

Authors:  Edmund Huang; Angela Q Maldonado; Christian Kjellman; Stanley C Jordan
Journal:  Am J Transplant       Date:  2021-09-13       Impact factor: 9.369

Review 2.  Harnessing the B Cell Response in Kidney Transplantation - Current State and Future Directions.

Authors:  Imran J Anwar; Isabel F DeLaura; Qimeng Gao; Joseph Ladowski; Annette M Jackson; Jean Kwun; Stuart J Knechtle
Journal:  Front Immunol       Date:  2022-06-09       Impact factor: 8.786

Review 3.  New Perspectives on Desensitization in the Current Era - An Overview.

Authors:  Vineeta Kumar; Jayme E Locke
Journal:  Front Immunol       Date:  2021-07-30       Impact factor: 7.561

4.  Dynamic Behaviour of Donor Specific Antibodies in the Early Period Following HLA Incompatible Kidney Transplantation.

Authors:  Mason Phillpott; Sunil Daga; Rob Higgins; David Lowe; Nithya Krishnan; Daniel Zehnder; David Briggs; Natalia Khovanova
Journal:  Transpl Int       Date:  2022-04-11       Impact factor: 3.842

5.  Imlifidase-generated Single-cleaved IgG: Implications for Transplantation.

Authors:  Robert Bockermann; Sofia Järnum; Anna Runström; Tomas Lorant; Lena Winstedt; Niklas Palmqvist; Christian Kjellman
Journal:  Transplantation       Date:  2021-12-27       Impact factor: 5.385

6.  European Guideline for the Management of Kidney Transplant Patients With HLA Antibodies: By the European Society for Organ Transplantation Working Group.

Authors:  Nizam Mamode; Oriol Bestard; Frans Claas; Lucrezia Furian; Siân Griffin; Christophe Legendre; Liset Pengel; Maarten Naesens
Journal:  Transpl Int       Date:  2022-08-10       Impact factor: 3.842

Review 7.  HLA Desensitization in Solid Organ Transplantation: Anti-CD38 to Across the Immunological Barriers.

Authors:  Nizar Joher; Marie Matignon; Philippe Grimbert
Journal:  Front Immunol       Date:  2021-05-20       Impact factor: 7.561

8.  Outcomes at 3 years posttransplant in imlifidase-desensitized kidney transplant patients.

Authors:  Christian Kjellman; Angela Q Maldonado; Kristoffer Sjöholm; Bonnie E Lonze; Robert A Montgomery; Anna Runström; Tomas Lorant; Niraj M Desai; Christophe Legendre; Torbjörn Lundgren; Bengt von Zur Mühlen; Ashley A Vo; Håkan Olsson; Stanley C Jordan
Journal:  Am J Transplant       Date:  2021-07-19       Impact factor: 9.369

9.  Imlifidase Desensitization in Crossmatch-positive, Highly Sensitized Kidney Transplant Recipients: Results of an International Phase 2 Trial (Highdes).

Authors:  Stanley C Jordan; Christophe Legendre; Niraj M Desai; Tomas Lorant; Mats Bengtsson; Bonnie E Lonze; Ashley A Vo; Anna Runström; Lena Laxmyr; Kristoffer Sjöholm; Åsa Schiött; Elisabeth Sonesson; Kathryn Wood; Lena Winstedt; Christian Kjellman; Robert A Montgomery
Journal:  Transplantation       Date:  2021-08-01       Impact factor: 5.385

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.